Atopic dermatitis

A novel, patient-tailored monoclonal antibody therapy has shown promise in treating moderate to severe atopic dermatitis.  Patients who participated in a clinical trial of rocatinlimab showed positive results while taking the drug and up to 20 weeks after stopping therapy, Mount Sinai researchers have reported in The Lancet.  The researchers said the results indicate that […]

A biologic therapy for very young children with moderate to severe eczema (or atopic dermatitis) has been shown to be safe and effective in an international trial. Sponsored by Regeneron and Sanofi, the study of dupilumab in poorly controlled eczema is the first large-scale randomised double-blind trial of a monoclonal antibody for any skin disease […]